Industries > Pharma > Global Smoking Cessation Drugs Market Forecast 2017-2027

Global Smoking Cessation Drugs Market Forecast 2017-2027

NRT, Non-nicotine Pharmacotherapy, Prescription Drugs, OTC Drugs

PUBLISHED: 31 October 2017
PAGES: 280
PRODUCT CODE: PHA0254

Clear
WOOCS 2.2.1
SKU: PHA0254 Categories: , ,

The global smoking cessation drugs market is expected to grow at a CAGR of 14.9% in the first half of the forecast period. In 2016, the non-nicotine pharmacotherapy submarket held 56.2% of the global smoking cessation drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 280-page report you will receive 175 tables and 150 figures– all unavailable elsewhere.

The 280-page report provides clear detailed insight into the global smoking cessation drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Global Smoking Cessation Drugs market forecasts from 2017-2027

• This report also breaks down the revenue forecast for the global smoking cessation drugs market by type of therapy:
– NRT
– Non-Nicotine Pharmacotherapy

• This report also breaks down the revenue forecast for the global smoking cessation drugs market by prescription vs OTC:
– Prescription drugs
– OTC

• This report provides individual revenue forecasts to 2027 for these regions:
– North America
– Europe
– Asia-Pacific
– RoW

Each region is further segmented by type of therapy.

Global Smoking Cessation Drugs Market Forecast 2017-2027

• This report provides the following qualitative analysis:
– Epidemiology by geography, available treatment options, along with humanistic and economic burden
– A SWOT Analysis
– Pipeline molecules which are under development for the treatment of smoking cessation and detailed analysis on promising drug candidates
– Pricing and reimbursement overview of the smoking cessation drugs market.
– Leading companies that are the major players in the global smoking cessation drugs industry, including Pfizer, GlaxoSmithKline and Johnson & Johnson.

Visiongain’s study is intended for anyone requiring commercial analyses for the global smoking cessation drugs market. You find data, trends and predictions.

Buy our report today Global Smoking Cessation Drugs Market Forecast 2017-2027: NRT, Non-nicotine Pharmacotherapy, Prescription Drugs, OTC Drugs.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Smoking Cessation Drugs Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Smoking Cessation Drugs Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

READ

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Categories